News

Corporate Press

26
24-01
Adcoris' Investigational New Drug Application for ACR246 as an Injectable Antibody-drug Conjugate for Solid Tumors Approved by NMPA
On January 26, 2024, Adcoris,a leading developer of the next generation antibody drug conjugation technology,announced that it has received clearance from the China National MedicalProducts Administration (NMPA) for its investigational new drug (IND)...
23
23-11
Adcoris' Investigational New Drug Application for ACR246 as an Injectable Antibody-drug Conjugate for Solid Tumors Accepted by NMPA
On November 22, 2023, an investigational new drug (IND) application for ACR246 by Adcoris was accepted by China National Medical Products Administration (NMPA). ACR246 is an injectable antibody-drug conjugate (ADC) that targets tumor associated antig...
03
23-11
2023 ESMO | Adcoris released preliminary Phase 1 results of ZV0203, a first-in-class pertuzumab ADC
Hangzhou Adcoris Biophama Co. Ltd (Adcoris) presented preliminary phase 1 clinical study results for ZV0203 (ADC2122) as a poster at the 2023 ESMO (European Society for Medical Oncology) Congress (Oct. 20-24, Madrid, Spain) that attracted over 33000 ...
27
23-10
Adcoris made its appearance at the 2023 World ADC Conference
From October 16 to 19 (Pacific Time), the 14th World ADC Conference was held in San Diego, USA. Adcoris was invited to participate.
27
23-09
Interview with Dr. Huang, VP of R&D of Adcoris:New drug R&D is a game of science versus reality and always seems to be full of surprise and unpredictability.
...
23
23-02
Business Development:Adcoris and Lunan Pharmaceutical Group reached a strategic collaboration agreement for an ADC product co-development.
December 2022, Hangzhou Adcoris Biopharma Co., LTD.(Adcoris) and Lunan Pharmaceutical Group (Lunan) announced that a strategic collaboration agreement was reached on the joint development of one to two ADC products. According to the agreement, Adcori...
22
23-02
Subject Recruitment
Recruitment Notice An open, multicenter Phase I dose-escalation study sponsored by Hangzhou Adcoris Biopharma Co., Ltd. to evaluate the safety, pharmacokinetics, immunogenicity, and initial antitumor activity of ZV0203 in patients with advanced solid...